Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


US downturn fails to halt Dantec's progress:

This article was originally published in Clinica

Executive Summary

Dantec Medical (Denmark) saw sales increase 9% in 1994 to DKr 198 million ($37 million), while pre-tax profits were DKr 11.6 million, compared with a loss of DKr 12 million in 1993. Some 97% of overall sales were exported, according to the annual report of Incentive, Dantec's parent company. Dantec, which claims to lead the world urology market, suffered a decline in US business during 1994 as a result of continued recession and the delay in FDA approval of the company's Keypoint EMG system. Dantec says it expects approval to be granted during 1995. This downturn was, however, more than offset by success in other markets, particularly Germany, Japan and China.

You may also be interested in...

US FDA Commissioner Hahn’s Star Turn: Baptism By Fire Turns Perilous

Stephen Hahn’s low visibility period as the newly installed FDA commissioner comes to an abrupt end. Trump offers generous praise amid COVID-19 response – but how quickly might that change to blame?

Keeping Track: US FDA Okays BMS’ Zeposia In MS, Nixes Lilly/BI’s Empagliflozin For Type 1 Diabetes

The latest drug development news and highlights from the Pink Sheet US FDA Performance Tracker.

US FDA Not Changing Assessment Goals Because of Coronavirus-Mandated Telework

Assessment work also isn’t slowing down, the new and generic drug office directors said in an interview, but approval data offers a note of concern.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts